Announcements
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
- Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
- Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
More ▼
Key statistics
As of last trade, Autolus Therapeutics PLC (6A3A:DUS) traded at 3.96, 102.04% above the 52 week low of 1.96 set on Oct 03, 2023.
52-week range
Open | 3.78 |
---|---|
High | 3.96 |
Low | 3.78 |
Bid | 3.90 |
Offer | 3.98 |
Previous close | 3.88 |
Average volume | 631.78 |
---|---|
Shares outstanding | 266.04m |
Free float | 8.82m |
P/E (TTM) | -- |
Market cap | 1.11bn USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of Jun 05 2024 18:32 BST.
More ▼